Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06282549

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

Sponsor: Yuhan Corporation

View on ClinicalTrials.gov

Summary

This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.

Official title: A Prospective Long-term Cohort Study to Identify the Predictive Model of Cardiocerebrovascular Risk Factors in Elderly Patients with More Than Three Antihypertensive Agents in Patients with Essential Hypertension in Korea

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1219

Start Date

2022-06-08

Completion Date

2027-03-31

Last Updated

2024-11-19

Healthy Volunteers

No

Interventions

DRUG

Telmisartan/Amlodipine/Chlorthalidone(Truset)

Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg

Locations (5)

Busan Veterans Hospital

Busan, South Korea

Daegu Veterans Hospital

Daegu, South Korea

Gwangju Veterans Hospital

Gwangju, South Korea

Konkuk University Medical Center

Seoul, South Korea

Veterans Health Service Medical Center

Seoul, South Korea